Persistent atrial fibrillation with left atrial low-voltage area: who benefit from additional modification?
Europace · 2025
DOI: 10.1093/europace/euaf095 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Europace, 2025. Verfasst von Hengzhi Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Guangzhou Road, Nanjing, 210029, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Pulmonary Veins, Heart Atria. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
The presence of low-voltage areas (LVAs) is associated with increased recurrence rate following ablation of persistent atrial fibrillation (PeAF). However, the benefit of additional LVA modification remains controversial. This substudy of the STABLE-SR-II trial aims to explore the factors that influence the benefit of additional LVA ablation for PeAF patients with LVAs. Methods and results In the STABLE-SR-II trial, PeAF patients with de novo ablation were randomized to receive either circumferential pulmonary vein isolation (CPVI, CPVI-alone group) or CPVI plus LVA ablation (CPVI-plus group). Patients with LVAs were included and analyzed in this substudy. The primary outcome was freedom from atrial arrhythmias 18 months after a single ablation procedure. LVAs were detected in 133 out of 276 PeAF patients (48%). Age and LVA burden were potential factors influencing the relative success of additional LVA ablation compared with CPVI alone in the univariable analysis. In multi-adjusted models, significant benefit from additional LVA ablation was found in patients aged ≥65 years [n = 50, hazard ratio (HR) 0.14, 95% confidence interval (CI) 0.02–0.83] or with LVA burden ≥ 15% (n = 18, HR 0.01, 95% CI: 0–0.44). LVA burden ≥15% was observed in 10 of 50 patients aged ≥65 years (20%) and in 8 of 83 patients aged <65 years (10%). Combined subgroup analysis demonstrated that LVA ablation was particularly beneficial for patients aged ≥65 years, regardless of LVA burden.
Conclusion
LVA ablation following CPVI may provide additional benefits for older PeAF patients (≥65 years) in the first procedure. Clinical Trial Registration NCT03448562 [CPVI Alone Versus CPVI Plus Electrophysiological Substrate Ablation in the LA During SR for the Treatment of Non-PAF (STABLE-SR_II)].
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Guangzhou Road, Nanjing, 210029, China.
ORCID-Profile: Hengzhi Zhang, Ning Chen, Qiuheng Bian, Gang Yang, Youmei Shen, Hongwu Chen, Weizhu Ju, Mingfang Li, Kai Gu, Hailei Liu, Minglong Chen
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, H., Chen, N., Bian, Q., Yuan, M., Yang, G., Shen, Y., Chen, H., Ju, W., Li, M., Gu, K., Wu, N., Liu, H., & Chen, M. (2025). Persistent atrial fibrillation with left atrial low-voltage area: who benefit from additional modification?. Europace. https://doi.org/10.1093/europace/euaf095
Vancouver
Zhang H, Chen N, Bian Q, Yuan M, Yang G, Shen Y, et al. Persistent atrial fibrillation with left atrial low-voltage area: who benefit from additional modification?. Europace. 2025. doi:10.1093/europace/euaf095
BibTeX
@article{Zhang2025,
author = {Zhang, Hengzhi and Chen, Ning and Bian, Qiuheng and Yuan, Mingchuan and Yang, Gang and Shen, Youmei and Chen, Hongwu and Ju, Weizhu and Li, Mingfang and Gu, Kai and Wu, Nan and Liu, Hailei and Chen, Minglong},
title = {Persistent atrial fibrillation with left atrial low-voltage area: who benefit from additional modification?},
journal = {Europace},
year = {2025},
doi = {10.1093/europace/euaf095}
}
EUVIMED